- Home
- IBRX vs MP Comparison
IBRX vs MP Comparison
Compare IBRX & MP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | MP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.0B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IBRX | MP |
|---|---|---|
| Price | $8.46 | $47.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $12.57 | ★ $75.25 |
| AVG Volume (30 Days) | ★ 8.4M | 4.8M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | $113,288,000.00 | ★ $331,952,000.00 |
| Revenue This Year | $88.59 | $100.51 |
| Revenue Next Year | $131.15 | $60.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 668.31 | 147.15 |
| 52 Week Low | $1.95 | $37.81 |
| 52 Week High | $12.43 | $100.25 |
Technical Indicators
Market Signals| Indicator | IBRX | MP |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 37.13 |
| Support Level | $6.68 | $44.43 |
| Resistance Level | $8.51 | $62.66 |
| Average True Range (ATR) | 0.40 | 2.26 |
| MACD | 0.02 | -0.94 |
| Stochastic Oscillator | 68.10 | 4.26 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.